Opinion|Videos|January 10, 2025
Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas
Panelists discuss how the sequencing of bispecific therapies in first-line vs later-line settings should be guided by factors such as disease stage, prior treatments, and patient-specific characteristics to optimize therapeutic outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What considerations should guide the sequencing of bispecific therapies in first-line vs later-line settings?
Advertisement
Related to this article
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
A prospective Italian study of 492 postmenopausal women found ultrasound signs of deep endometriosis in 7.3%, often plaque-like and poorly vascularized.
AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.
A new tool puts this year's measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.
Earlier Alzheimer disease detection is outpacing specialist capacity and may widen gaps for underserved patients, Cleveland experts say.
Young adults with cancer symptoms often fall outside screening guidelines, face costly imaging, and go undiagnosed longer, oncologists say.
Eosinophil thresholds and documentation rules shape COPD biologic access. At ERS 2026, experts discussed biomarkers, delays, and multidisciplinary care.
Advertisement
Advertisement